Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 18

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 18
---
 the caption “Risk Factors” and other information in this Prospectus for a discussion of factors you should                                  
 carefully consider before deciding to invest in our Common Stock.                                                                           |

| (1) | As                   
 of December 12, 2025 |

| (2) | The                                                                                                                                 
 number of shares of our Common Stock that will be outstanding after this Offering is based on 60,729,100 shares of our Common Stock 
 outstanding as of December 12, 2025 and excludes:                                                                                   |

| ● | 4,270,000                                                                                                                        
 shares of Common stock issuable upon the exercise of outstanding stock options as of September 30, 2025, granted pursuant to our 
 Global Share Incentive Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.0.30 per            
 share and                                                                                                                        |

| ● | 2,930,000                                                                                                                       
 shares of Common Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of December 12, 2025 |

| ● | 6,372,265 Common Stock                                                                                                                
 issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 
 31, 2026.                                                                                                                             |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>4

RISK FACTOR SUMMARY</div>

The following is a summary
of the principal risks that could adversely affect our business, operations, and financial results. A more thorough discussion of these
and other risks are listed under the section entitled “Risk Factors” commencing on page 5.

Risks Relating to the Company’s Business and Financial Position

| ● | We have a History of Losses                                                                                                              
 and May Never Achieve Profitability.                                                                                                     |
| ● | We will need substantial                                                                                                                 
 additional funding to realize our business plan. We may not be able to raise capital when needed, if at all, which would force us        
 to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.        |
| ● | We anticipate that we can                                                                                                                
 successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to        
 comply with LipoVation’s contractual obligations under the Yissum License Agreements or other licenses or related